{"id":"W2953748643","doi":"10.1200/jco.2006.24.18_suppl.533","title":"Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Epirubicin; Breast cancer; Anthracycline; Internal medicine; Cyclophosphamide; Hazard ratio; Chemotherapy; Tissue microarray; Oncology; Cancer; Gynecology; Gastroenterology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001364838,0.0007831999,0.001647738,0.0003642298,0.000257194,0.00070938,0.0005892288,0.001343586,0.003260551],"category_scores_gemma":[0.002764226,0.0003517463,0.001342713,0.0003426351,0.0006491232,0.0005098646,0.0002894135,0.00162873,0.0002924142],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009821914,"about_ca_system_score_gemma":0.0009757404,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001868549,"about_ca_topic_score_gemma":0.004230746,"domain_scores_codex":[0.9993217,0.0004297735,0.00003228236,0.00008757631,0.00003184637,0.00009683087],"domain_scores_gemma":[0.9988122,0.0004255569,0.0002501925,0.00005823203,0.00004299165,0.0004108355],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9814077,0.001373776,0.004645999,0.0001297226,0.0005719564,0.00003796791,0.00002133625,0.0002802836,0.001106813,0.00004100114,0.0003554294,0.01002792],"study_design_scores_gemma":[0.8139285,0.1498615,0.03047528,0.00009800786,0.001896739,0.0000988773,0.00004984031,0.00177239,0.0005904124,0.0002150576,0.0009894776,0.00002387399],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941849,0.003593489,0.0000908119,0.000804178,0.0002183059,0.0003612067,0.0002367406,0.00001890301,0.0004914629],"genre_scores_gemma":[0.9974981,0.0007110446,0.0001872218,0.0003908783,0.0002054961,0.0003611773,0.0002778607,0.000002366757,0.0003658954],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003260551,"threshold_uncertainty_score":0.01090765,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02351475919426307,"score_gpt":0.3650299615452188,"score_spread":0.3415152023509557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}